Q32 Bio's Cash, Cash Equivalents, And Short-term Investments Of $107.6M As Of June 30, 2024, Expected To Provide Financial Runway Through Four Phase 2 Clinical Milestones And Into Mid-2026
Q32 Bio's Cash, Cash Equivalents, And Short-term Investments Of $107.6M As Of June 30, 2024, Expected To Provide Financial Runway Through Four Phase 2 Clinical Milestones And Into Mid-2026
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.